Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism


Author index

Page Path
Eon Ju Jeon  (Jeon EJ) 5 Articles
A Calcitonin-Negative Neuroendocrine Tumor Derived from Follicular Lesions of the Thyroid
Ga Young Kim, Chul Yun Park, Chang Ho Cho, June Sik Park, Eui Dal Jung, Eon Ju Jeon
Endocrinol Metab. 2015;30(2):221-225.   Published online December 9, 2014
  • 3,193 View
  • 29 Download
  • 7 Web of Science
  • 8 Crossref
AbstractAbstract PDFPubReader   

Neuroendocrine lesions of the thyroid are rare. The most common types are medullary thyroid carcinomas (MTCs) and C-cell hyperplasia. MTCs originate from thyroid parafollicular cells that secrete calcitonin which serves as a serum marker of MTCs. Here, the rare case of a calcitonin-negative neuroendocrine tumor (NET) derived from follicular lesions of the thyroid is described. A 34-year-old man presented at our hospital for the surgical management of an incidental thyroid nodule that was observed on an ultrasound sonography (USG) of the neck. Initially, USG-guided aspiration cytology was performed, and a MTC was suspected. The expressions of thyroglobulin and thyroid transcription factor-1, which are thyroid follicular cell markers, and synaptophysin and chromogranin A, which are neuroendocrine markers, was confirmed following surgical pathology. However, the staining of calcitonin, a marker of MTCs, was not observed. A nonmedullary NET of the thyroid is uncommon, and the distinction between calcitonin-negative NETs and MTCs of the thyroid may be important due to differences in their clinical courses and management.


Citations to this article as recorded by  
  • Calcitonin-Negative Neuroendocrine Carcinoma of the Thyroid Gland: Case Report and Literature Review
    Ricardo Fernández-Ferreira, Ildefonso Roberto De la Peña-López, Karla Walkiria Zamudio-Coronado, Luis Antonio Delgado-Soler, María Eugenia Torres-Pérez, Christianne Bourlón-de los Ríos, Rubén Cortés-González
    Case Reports in Oncology.2021; 14(1): 112.     CrossRef
  • Calcitonin-negative neuroendocrine tumor of the thyroid with metastasis to liver-rare presentation of an unusual tumor: A case report and review of literature
    Huai-Jie Cai, Han Wang, Nan Cao, Bin Huang, Fan-Lei Kong, Li-Ren Lu, Ya-Yuan Huang, Wei Wang
    World Journal of Clinical Cases.2020; 8(1): 179.     CrossRef
  • Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review
    Claudio Gambardella, Chiara Offi, Guglielmo Clarizia, Roberto Maria Romano, Immacolata Cozzolino, Marco Montella, Rosa Maria Di Crescenzo, Massimo Mascolo, Angelo Cangiano, Sergio Di Martino, Giancarlo Candela, Giovanni Docimo
    BMC Endocrine Disorders.2019;[Epub]     CrossRef
  • Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?
    Claudio Gambardella, Chiara Offi, Renato Patrone, Guglielmo Clarizia, Claudio Mauriello, Ernesto Tartaglia, Francesco Di Capua, Sergio Di Martino, Roberto Maria Romano, Lorenzo Fiore, Alessandra Conzo, Giovanni Conzo, Giovanni Docimo
    BMC Endocrine Disorders.2019;[Epub]     CrossRef
  • Calcitonin-Negative Neuroendocrine Tumor of the Thyroid
    Megan Parmer, Stacey Milan, Alireza Torabi
    International Journal of Surgical Pathology.2017; 25(2): 191.     CrossRef
  • Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin
    Qiufeng Zhou, Shuanglei Yue, Ye Cheng, Ju Jin, Haimiao Xu
    Experimental and Toxicologic Pathology.2017; 69(8): 575.     CrossRef
  • Primary Calcitonin-negative Neuroendocrine Tumor
    Sabri Özden, Aysel Colak, Baris Saylam, Ömer Cengiz
    World Journal of Endocrine Surgery.2017; 9(3): 104.     CrossRef
    I. N. Zubarovskiy, M. V. Mikhailova, S. K. Osipenko
    Grekov's Bulletin of Surgery.2015; 174(5): 32.     CrossRef
Close layer
Close layer
Diagnostic Whole-Body Scan May Not Be Necessary for Intermediate-Risk Patients with Differentiated Thyroid Cancer after Low-Dose (30 mCi) Radioactive Iodide Ablation
Eon Ju Jeon, Eui Dal Jung
Endocrinol Metab. 2014;29(1):33-39.   Published online March 14, 2014
  • 3,745 View
  • 31 Download
  • 10 Web of Science
  • 9 Crossref
AbstractAbstract PDFPubReader   

A diagnostic whole-body scan (WBS) is recommended 6 to 12 months after total thyroidectomy and radioactive iodide ablation in intermediate- or high-risk patients with differentiated thyroid cancer (DTC). The aim of this study was to evaluate the necessity of a diagnostic WBS after radioactive iodide ablation in intermediate-risk patients with DTC.


A total of 438 subjects were included in the study: 183 low-risk subjects and 255 intermediate-risk subjects according to the American Thyroid Association guideline. All subjects diagnosed with DTC received 1,100 MBq (30 mCi) activity of radioiodine (I-131) following total thyroidectomy. On follow-up, all subjects underwent a diagnostic I-131 WBS after thyroid hormone withdrawal.


After initial radioactive iodide ablation, 95.1% of low-risk patients and 91.4% of intermediate-risk patients showed no uptake on diagnostic WBS (P=0.135). Intermediate-risk patients with stimulated thyroglobulin (Tg) levels higher than 2.0 ng/mL showed a greater rate of radioactive iodine uptake on diagnostic WBS. Four intermediate-risk patients showed recurrence during the 16 to 80 months follow-up period. Three of the four patients with recurrence showed no uptake on diagnostic WBS and had a stimulated Tg level less than 2.0 ng/mL.


A diagnostic I-131 WBS after radioactive iodide ablation in intermediate-risk patients with DTC may not be necessary. A large prospective study is necessary to determine the necessity of diagnostic WBS in intermediate-risk patients with DTC.


Citations to this article as recorded by  
  • Long-Term Prognostic Value of the Response to Therapy Assessed by Laboratory and Imaging Findings in Patients with Differentiated Thyroid Cancer
    Michele Klain, Emilia Zampella, Leandra Piscopo, Fabio Volpe, Mariarosaria Manganelli, Stefania Masone, Leonardo Pace, Domenico Salvatore, Martin Schlumberger, Alberto Cuocolo
    Cancers.2021; 13(17): 4338.     CrossRef
  • Lack of Efficacy of Radioiodine Remnant Ablation for Papillary Thyroid Microcarcinoma: Verification Using Inverse Probability of Treatment Weighting
    Hyemi Kwon, Min Ji Jeon, Won Gu Kim, Suyeon Park, Mijin Kim, Tae Yong Kim, Minkyu Han, Dong Eun Song, Tae-Yon Sung, Jong Ho Yoon, Suck Joon Hong, Jin-Sook Ryu, Young Kee Shong, Won Bae Kim
    Annals of Surgical Oncology.2017; 24(9): 2596.     CrossRef
  • Evaluation of 131I scintigraphy and stimulated thyroglobulin levels in the follow up of patients with DTC: a retrospective analysis of 1420 patients
    Jose Manuel Gonzalez Carvalho, Dennis Görlich, Otmar Schober, Christian Wenning, Burkhard Riemann, Frederik Anton Verburg, Alexis Vrachimis
    European Journal of Nuclear Medicine and Molecular Imaging.2017; 44(5): 744.     CrossRef
  • Low- and high-dose radioiodine therapy for low-/intermediate-risk differentiated thyroid cancer: a preliminary clinical trial
    Yuan Qu, Rui Huang, Lin Li
    Annals of Nuclear Medicine.2017; 31(1): 71.     CrossRef
  • ENDOCRINE TUMOURS: Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach
    Livia Lamartina, Désirée Deandreis, Cosimo Durante, Sebastiano Filetti
    European Journal of Endocrinology.2016; 175(5): R185.     CrossRef
  • The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative 131I dose over 37 GBq
    Ah Reum Khang, Sun Wook Cho, Hoon Sung Choi, Hwa Young Ahn, Won Sang Yoo, Kyung Won Kim, Keon Wook Kang, Ka Hee Yi, Do Joon Park, Dong Soon Lee, June‐Key Chung, Bo Youn Cho, Young Joo Park
    Clinical Endocrinology.2015; 83(1): 117.     CrossRef
  • Articles in 'Endocrinology and Metabolism' in 2014
    Won-Young Lee
    Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
  • Recent Changes in the Clinical Outcome of Papillary Thyroid Carcinoma With Cervical Lymph Node Metastasis
    Min Ji Jeon, Won Gu Kim, Yun Mi Choi, Hyemi Kwon, Dong Eun Song, Yu-Mi Lee, Tae-Yon Sung, Jong Ho Yoon, Suck Joon Hong, Jung Hwan Baek, Jeong Hyun Lee, Jin-Sook Ryu, Tae Yong Kim, Young Kee Shong, Ki-Wook Chung, Won Bae Kim
    The Journal of Clinical Endocrinology & Metabolism.2015; 100(9): 3470.     CrossRef
  • Letter: Diagnostic Whole-Body Scan May Not Be Necessary for Intermediate-Risk Patients with Differentiated Thyroid Cancer after Low-Dose (30 mCi) Radioactive Iodide Ablation (Endocrinol Metab 2014;29:33-9, Eon Ju Jeon et al.)
    Chan-Hee Jung
    Endocrinology and Metabolism.2014; 29(2): 206.     CrossRef
Close layer
A Case of Parathyroid Apoplexy of Primary Hyperparathyroidism Presenting as Auditory Hallucinations Accompanied with Hypocalcemia.
Eon Ju Jeon, Ji Yun Jeong, Jung Guk Kim
Endocrinol Metab. 2012;27(2):163-168.   Published online June 20, 2012
  • 22,334 View
  • 23 Download
AbstractAbstract PDF
The natural history of primary hyperparathyroidism, due to parathyroid adenoma, is unknown. Furthermore, spontaneous resolution of parathyroid necrosis or hemorrhage is rare and usually asymptomatic. Here, we report a case of parathyroid apoplexy of primary hyperparathyroidism, presenting as auditory hallucinations, accompanied with hypocalcemia. A 39-year-old man who was incidentally diagnosed with primary hyperparathyroidism, and waiting surgery for parathyroidectomy presented to psychiatric service with auditory hallucinations. He developed tetany, while taking psychiatric drugs. On a follow-up investigation, his serum calcium level fell from 11.8 to 5.8 mg/dL. His intact parathyroid hormone level also decreased from 1,017 pg/mL to 71.1 pg/mL. The parathyroid apoplexy was confirmed after a surgical removal of the infarcted adenoma. The auditory hallucinations disappeared, and serum calcium level was returned to within the normal range.
Close layer
A Case of Dopamine-Secreting Pheochromocytoma.
Jung Kyu Park, Hoon Kyu Oh, Moo Hyun Shon, Hyun Hee Kim, Eon Ju Jeon, Eui Dal Jung
Endocrinol Metab. 2012;27(2):159-162.   Published online June 20, 2012
  • 65,829 View
  • 33 Download
  • 1 Crossref
AbstractAbstract PDF
A pheochromocytoma is a neuroectodermal tumor that originates from the chromaffin cells of the sympathetic system. It has typical symptoms or signs, such as periodic attacks of paroxysmal hypertension, palpitation, headache, and sweating, related to an increased catecholamine secretion. Types of catecholamine secreted from tumors are usually norepinephrine and epinerphrine. There are a few reports of dopamine-secreting pheochromocytoma with absence of other catecholamines secretion. Here, we report the case of a 59-year-old man with dopamine-secreting pheochromocytoma, with no typical symptoms or signs.


Citations to this article as recorded by  
  • Metanephrine negative pheochromocytoma: a rare case report of dopamine-secreting tumor in an adolescent neurofibromatosis type 1 patient
    Mi-Seon Lee, Rosie Lee, Sook-Hyun Park, Soon Hak Kwon, Jin-Young Park, Sang-Woo Lee, So-Mi Lee, Jung-Eun Moon
    Annals of Pediatric Endocrinology & Metabolism.2023; 28(4): 302.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism